Virpax Pharmaceuticals Valuation
| VRPX Stock | USD 2.07 0.43 17.20% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Virpax Pharmaceuticals has a current Real Value of $2.49 per share. The regular price of the company is $2.07. Our model measures the value of Virpax Pharmaceuticals from inspecting the company fundamentals such as Shares Outstanding of 4.89 M, return on equity of -3.62, and Shares Owned By Institutions of 0.03 % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Virpax Pharmaceuticals' valuation include:
Undervalued
Today
Please note that Virpax Pharmaceuticals' price fluctuation is dangerous at this time. Calculation of the real value of Virpax Pharmaceuticals is based on 3 months time horizon. Increasing Virpax Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Virpax Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Virpax Stock. However, Virpax Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.07 | Real 2.49 | Target 3.0 | Hype 2.98 | Naive 2.48 |
The intrinsic value of Virpax Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Virpax Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Virpax Pharmaceuticals helps investors to forecast how Virpax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Virpax Pharmaceuticals more accurately as focusing exclusively on Virpax Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Virpax Pharmaceuticals' intrinsic value based on its ongoing forecasts of Virpax Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Virpax Pharmaceuticals' closest peers.
Virpax Pharmaceuticals Cash |
|
Virpax Valuation Trend
Analysing the historical paterns of Virpax Pharmaceuticals' enterprise value and its market capitalization is a good way to estimate and gauge the value of Virpax Pharmaceuticals over time and is usually enough for investors to make rational market timing decisions.
Virpax Pharmaceuticals Total Value Analysis
Virpax Pharmaceuticals is at this time projected to have valuation of 654.45 K with market capitalization of 3.03 M, debt of 2.47 B, and cash on hands of 26.06 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Virpax Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
654.45 K | 3.03 M | 2.47 B | 26.06 M |
Virpax Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Virpax is to check how much profit was generated for every dollar of assets it reports. Virpax Pharmaceuticals has a negative utilization of assets of -0.91 %, losing $0.009142 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Virpax Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Virpax Pharmaceuticals Ownership Allocation
About 97.4 % of Virpax Pharmaceuticals outstanding shares are held by general public with 2.57 (%) owned by insiders and only 0.03 % by institutional holders.Virpax Pharmaceuticals Profitability Analysis
Net Loss for the year was (12.07 B) with profit before overhead, payroll, taxes, and interest of 0.About Virpax Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Virpax Pharmaceuticals. We calculate exposure to Virpax Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Virpax Pharmaceuticals's related companies.Virpax Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 4.3 M |
Virpax Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Virpax Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Virpax we look at many different elements of the entity such as Virpax's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Virpax Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Virpax Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Virpax Pharmaceuticals' worth.Additional Tools for Virpax Stock Analysis
When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.